Format

Send to

Choose Destination
Clin Interv Aging. 2018 Dec 28;14:73-79. doi: 10.2147/CIA.S159148. eCollection 2019.

RAB10: an Alzheimer's disease resilience locus and potential drug target.

Author information

1
Department of Biology, Brigham Young University, Provo, UT 84602, USA.
2
Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA, karchc@wustl.edu.
3
Department of Neuroscience, Brigham Young University, Provo, UT 84602, USA.
4
Hope Center for Neurological Disorders, Washington University in St Louis, St Louis, MO, USA, karchc@wustl.edu.

Abstract

Alzheimer's disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.

KEYWORDS:

APP; Alzheimer’s disease; GTPase; RAB10; resilience; retromer

PMID:
30643396
PMCID:
PMC6312396
DOI:
10.2147/CIA.S159148
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center